Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GT103 |
Synonyms | |
Therapy Description |
GT103 inhibits CFH, which potentially induces complement-dependent tumor cell killing, increases antitumor immune response, and decreases tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 9128)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GT103 | GT-103|GT 103 | GT103 inhibits CFH, which potentially induces complement-dependent tumor cell killing, increases antitumor immune response, and decreases tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 9128)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04314089 | Phase I | GT103 | Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) | Active, not recruiting | USA | 0 |